Patients with myasthenia gravis (MG) who have one copy of an FCGRT gene variant have lower levels of circulating antibodies called immunoglobulin G (IgG) and are more likely to be resistant to intravenous immunoglobulin (IVIg) treatment, a small study found. The results suggest that both the gene variant and the lower levels of antibodies may be predictive markers for poor responses to IVIG in people with MG, investigators said. The study, “VNTR2/VNTR3 genotype in the FCGRT gene…

You must be logged in to read/download the full post.